The number needed to treat for second-generation biologics when treating established rheumatoid arthritis: a systematic quantitative review of randomized controlled trials

L E Kristensen; A K Jakobsen; E M Bartels; P Geborek; H Bliddal; T Saxne; B Danneskiold-Samsøe; R Christensen

doi:http://dx.doi.org/10.3109/03009742.2010.491834

The number needed to treat for second-generation biologics when treating established rheumatoid arthritis: a systematic quantitative review of randomized controlled trials

L E Kristensen, A K Jakobsen, E M Bartels, P Geborek, H Bliddal, T Saxne, B Danneskiold-Samsøe, R Christensen

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

23 Citationer (Scopus)

Abstract

To evaluate the number needed to treat (NNT) and the number needed to harm (NNH) of the second-generation biologics abatacept, certolizumab, golimumab, rituximab, and tocilizumab in patients with established rheumatoid arthritis (RA) taking concomitant methotrexate (MTX).

Originalsprog	Engelsk
Tidsskrift	Scandinavian Journal of Rheumatology
Vol/bind	40
Udgave nummer	1
Sider (fra-til)	1-7
Antal sider	7
ISSN	0300-9742
DOI	https://doi.org/10.3109/03009742.2010.491834
Status	Udgivet - 2011

Adgang til dokumentet

http://dx.doi.org/10.3109/03009742.2010.491834

Citationsformater

Kristensen, L. E., Jakobsen, A. K., Bartels, E. M., Geborek, P., Bliddal, H., Saxne, T., Danneskiold-Samsøe, B., & Christensen, R. (2011). The number needed to treat for second-generation biologics when treating established rheumatoid arthritis: a systematic quantitative review of randomized controlled trials. Scandinavian Journal of Rheumatology, 40(1), 1-7. https://doi.org/10.3109/03009742.2010.491834

The number needed to treat for second-generation biologics when treating established rheumatoid arthritis : a systematic quantitative review of randomized controlled trials. / Kristensen, L E; Jakobsen, A K; Bartels, E M; Geborek, P; Bliddal, H; Saxne, T; Danneskiold-Samsøe, B; Christensen, R.

I: Scandinavian Journal of Rheumatology, Bind 40, Nr. 1, 2011, s. 1-7.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

Kristensen, LE, Jakobsen, AK, Bartels, EM, Geborek, P, Bliddal, H, Saxne, T, Danneskiold-Samsøe, B & Christensen, R 2011, 'The number needed to treat for second-generation biologics when treating established rheumatoid arthritis: a systematic quantitative review of randomized controlled trials', Scandinavian Journal of Rheumatology, bind 40, nr. 1, s. 1-7. https://doi.org/10.3109/03009742.2010.491834

Kristensen, L E ; Jakobsen, A K ; Bartels, E M ; Geborek, P ; Bliddal, H ; Saxne, T ; Danneskiold-Samsøe, B ; Christensen, R. / The number needed to treat for second-generation biologics when treating established rheumatoid arthritis : a systematic quantitative review of randomized controlled trials. I: Scandinavian Journal of Rheumatology. 2011 ; Bind 40, Nr. 1. s. 1-7.

@article{cdc1455a25ba433faa30811a7178f9e2,

title = "The number needed to treat for second-generation biologics when treating established rheumatoid arthritis: a systematic quantitative review of randomized controlled trials",

abstract = "To evaluate the number needed to treat (NNT) and the number needed to harm (NNH) of the second-generation biologics abatacept, certolizumab, golimumab, rituximab, and tocilizumab in patients with established rheumatoid arthritis (RA) taking concomitant methotrexate (MTX).",

author = "Kristensen, {L E} and Jakobsen, {A K} and Bartels, {E M} and P Geborek and H Bliddal and T Saxne and B Danneskiold-Sams{\o}e and R Christensen",

year = "2011",

doi = "http://dx.doi.org/10.3109/03009742.2010.491834",

language = "English",

volume = "40",

pages = "1--7",

journal = "Scandinavian Journal of Rheumatology",

issn = "0300-9742",

publisher = "Taylor & Francis",

number = "1",

}

TY - JOUR

T1 - The number needed to treat for second-generation biologics when treating established rheumatoid arthritis

T2 - a systematic quantitative review of randomized controlled trials

AU - Kristensen, L E

AU - Jakobsen, A K

AU - Bartels, E M

AU - Geborek, P

AU - Bliddal, H

AU - Saxne, T

AU - Danneskiold-Samsøe, B

AU - Christensen, R

PY - 2011

Y1 - 2011

N2 - To evaluate the number needed to treat (NNT) and the number needed to harm (NNH) of the second-generation biologics abatacept, certolizumab, golimumab, rituximab, and tocilizumab in patients with established rheumatoid arthritis (RA) taking concomitant methotrexate (MTX).

AB - To evaluate the number needed to treat (NNT) and the number needed to harm (NNH) of the second-generation biologics abatacept, certolizumab, golimumab, rituximab, and tocilizumab in patients with established rheumatoid arthritis (RA) taking concomitant methotrexate (MTX).

U2 - http://dx.doi.org/10.3109/03009742.2010.491834

DO - http://dx.doi.org/10.3109/03009742.2010.491834

M3 - Journal article

VL - 40

SP - 1

EP - 7

JO - Scandinavian Journal of Rheumatology

JF - Scandinavian Journal of Rheumatology

SN - 0300-9742

IS - 1

ER -